ABX209: Phase II Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer.

Trial Profile

ABX209: Phase II Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin; Gemcitabine
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Sep 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 08 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top